| A general strategy for creating “inactive-conformation” abl inhibitors B Okram, A Nagle, FJ Adrián, C Lee, P Ren, X Wang, T Sim, Y Xie, ... Chemistry & biology 13 (7), 779-786, 2006 | 205 | 2006 |
| Smart factory in Industry 4.0 Z Shi, Y Xie, W Xue, Y Chen, L Fu, X Xu Systems Research and Behavioral Science 37 (4), 607-617, 2020 | 186 | 2020 |
| The challenges and countermeasures of blockchain in finance and economics L Zhang, Y Xie, Y Zheng, W Xue, X Zheng, X Xu Systems Research and Behavioral Science 37 (4), 691-698, 2020 | 175 | 2020 |
| Leadership style and innovation atmosphere in enterprises: An empirical study Y Xie, W Xue, L Li, A Wang, Y Chen, Q Zheng, Y Wang, X Li Technological Forecasting and Social Change 135, 257-265, 2018 | 164 | 2018 |
| Progress of electroplating and electroless plating on magnesium alloy L Wu, J Zhao, Y Xie, Z Yang Transactions of Nonferrous Metals Society of China 20, s630-s637, 2010 | 121 | 2010 |
| A type-II kinase inhibitor capable of inhibiting the T315I “gatekeeper” mutant of Bcr-Abl HG Choi, P Ren, F Adrian, F Sun, HS Lee, X Wang, Q Ding, G Zhang, ... Journal of medicinal chemistry 53 (15), 5439-5448, 2010 | 85 | 2010 |
| Intelligent supply chain performance measurement in Industry 4.0 Y Xie, Y Yin, W Xue, H Shi, D Chong Systems Research and Behavioral Science 37 (4), 711-718, 2020 | 79 | 2020 |
| Discovery and characterization of clinical candidate LXE408 as a kinetoplastid-selective proteasome inhibitor for the treatment of leishmaniases A Nagle, A Biggart, C Be, H Srinivas, A Hein, D Caridha, RJ Sciotti, ... Journal of Medicinal Chemistry 63 (19), 10773-10781, 2020 | 67 | 2020 |
| Compounds and compositions as protein kinase inhibitors Q Ding, Y Xie, NS Gray, S You, G Chopiuk, J Jiang, Y Liu, R Steensma, ... US Patent 7,449,582, 2008 | 57 | 2008 |
| Developmental and reproductive characteristics of western mosquitofish (Gambusia affinis) exposed to paper mill effluent in the Dengcun River, Sihui, South China L Hou, Y Xie, G Ying, Z Fang Aquatic toxicology 103 (3-4), 140-149, 2011 | 55 | 2011 |
| Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor δ agonists R Epple, C Cow, Y Xie, M Azimioara, R Russo, X Wang, J Wityak, ... Journal of medicinal chemistry 53 (1), 77-105, 2010 | 55 | 2010 |
| Altered development and reproduction in western mosquitofish (Gambusia affinis) found in the Hanxi River, southern China YP Xie, ZQ Fang, LP Hou, GG Ying Environmental Toxicology and Chemistry 29 (11), 2607-2615, 2010 | 52 | 2010 |
| 3, 4, 5-Trisubstituted isoxazoles as novel PPARδ agonists. Part 2 R Epple, M Azimioara, R Russo, Y Xie, X Wang, C Cow, J Wityak, ... Bioorganic & Medicinal Chemistry Letters 16 (21), 5488-5492, 2006 | 47 | 2006 |
| Compositions and methods for fgf receptor kinases inhibitors P Ren, G Zhang, S You, T Sim, NS Gray, Y Xie, X Wang, Y He US Patent App. 12/300,088, 2009 | 46 | 2009 |
| Free Radical Approach to Directed Aldol-Type Reactions Promoted by Allylic O-Stannyl Ketyls EJ Enholm, Y Xie, KA Abboud The Journal of Organic Chemistry 60 (5), 1112-1113, 1995 | 46 | 1995 |
| 3, 4, 5-Trisubstituted isoxazoles as novel PPARδ agonists: Part 1 R Epple, R Russo, M Azimioara, C Cow, Y Xie, X Wang, J Wityak, ... Bioorganic & medicinal chemistry letters 16 (16), 4376-4380, 2006 | 40 | 2006 |
| The impact of Industry 4.0 on organizational performance: the case of Pakistan's retail industry S Ali, Y Xie European Journal of Management Studies 26 (2/3), 63-86, 2021 | 38 | 2021 |
| Compounds and compositions as protein kinase inhibitors P Albaugh, GB Chopiuk, Q Ding, S Huang, Z Liu, S Pan, P Ren, X Wang, ... US Patent 8,202,876, 2012 | 38 | 2012 |
| Artificial intelligence leads the reform of education models J Qu, Y Zhao, Y Xie Systems Research and Behavioral Science 39 (3), 581-588, 2022 | 36 | 2022 |
| Immunosuppressant compounds and compositions S Pan, T Marsilje, W Lu, W Gao, NS Gray, Y He, Y Liu, Y Mi, Y Xie US Patent 7,572,811, 2009 | 36 | 2009 |
